IV-275

• UNSPSC Description:

  IV-275 is an inhibitor of both BRG1 and BRM bromodomains. IV-275 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-275 inhibits the invasiveness of GBM cells. IV-275 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide[1].

• Target Antigen:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/iv-275.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC=C(N2[C@H]3CN([C@@H](C2)C3)C(OC4=CC(F)=C(C=C4)F)=O)C=C1

• Molecular Weight:

  360.35

• References & Citations:

  [1]Yang C, et al. Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma. J Cell Mol Med. 2023 Sep;27(18):2770-2781.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported